Author Archives: Marisa Wexler MS

PH Patients at High Risk of Misusing Opioids After Surgery

People with pulmonary hypertension (PH) who start treatment with opioids to manage pain after undergoing surgery are at high risk of continuing to take these addictive medications for longer than required, new research suggests. Indeed, hypertension was one of eight specifically identified “top risk factors” for “new persistent post-surgical…

Blocking Specific PI3K Protein Prevents PH in Animal Models

Targeting a protein called p110a, a part of the PI3K family of enzymes, may be useful for preventing or even reversing pulmonary hypertension, research done in cells and rodent models showed. “Targeted inhibition of [p110a] offers a disease-modifying treatment approach, which is readily accessible by small molecule inhibitors and…

Potential PAH Therapy, KER-012 Also Prevents Bone Loss in Rat Model

A lab version of an investigational treatment for bone disorders and pulmonary arterial hypertension (PAH), KER-012 prevented bone loss in a PAH rat model, its developer, Keros Therapeutics, reported. Separate preclinical data in a PAH rat model, presented by the company earlier this year, also demonstrated that KER-012 worked to…

Potential Way of Treating PAH Seen in Blocking Specific MicroRNA

Blocking the activity of a small RNA molecule called microRNA-30a eased alterations in heart structure and blood vessel architecture in mouse models of pulmonary arterial hypertension (PAH), a new study reports. Results also showed that this molecule is present at abnormally high levels in PAH patients, supporting its potential…

Variation in Blood Vessel Anatomy May Raise Risk of CTEPH

Many people with chronic thromboembolic pulmonary hypertension or CTEPH have a particular anatomical variation called May-Thurner anatomy, which may increase the risk of developing this rare disease type, according to researchers. A new study found this anomaly is very common in individuals with CTEPH, with nearly 30% of patients…

Low-alcohol Red Wine Reduced PAH Symptoms in Rats

Regularly consuming low-alcohol red wine reduced signs of pulmonary arterial hypertension (PAH) in a rat model of the disease, a study shows. “The results of this study suggest that chronic moderate consumption of RARW [reduced-alcohol red wine] or its components may represent a promising new protective strategy to limit…

Bayer Doles Out $1M of Its PHAB Awards to 7 Research Projects

As part of the company’s Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, Bayer is giving a total of $1 million to seven research projects related to pulmonary hypertension. The awards are aimed at projects focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), which makes the…

Apabetalone Fares Well in Early Clinical Trial

Apabetalone (RVX-208), Resverlogix‘s experimental treatment for pulmonary arterial hypertension (PAH), was well-tolerated in a small clinical trial, the company announced. The trial met its primary goal of adding apabetalone to standard care to improve pulmonary vascular resistance (PVR), a measure that reflects the internal resistance to blood…